Page 402«..1020..401402403404..410420..»

New Cardiac Stem Cell Therapy passes Phase I/II Trials – Labiotech.eu (blog)

By JoanneRUSSELL25

TiGenix announces positiveone-year results forits phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI).

The Belgian biotech TiGenixis developing allogeneic stem cell therapies. Now the companyhasannouncedthat its cardiac stem cell therapyAlloCSC-01 reached its primary endpoints in aphase I/IItrial.

In 2015, the companyacquired Coretherapixin a292M deal for its allogeneic cardiac stem cell pipeline, which is being developed for the treatment of AMI.The first-in-human trial was designed to test the safety and feasibility of an intracoronary infusion of donor-derivedexpanded cardiac stem cells (AlloCSCs)in patients with AMI and left ventricular dysfunction.

AlloCSC-01consists of adult allogeneic cardiac stem cells isolated from the heartof donors and expanded in vitro. In vivo studies suggest that these cellshave cardio-reparative potential by activating regenerative pathways and promoting the formation of new hearttissue.

Thecurrent phase II study demonstrated thesafety of these allogeneic stem cells. Initial results also revealed a larger reduction of infarct size in a subgroup of patients.

Myocardial infarction caused by blockade of coronary arteries

TiGenix is well known forChondroCellect, which was the first cell therapyto reach the European market for the repair of knee cartilage.After the companyrecently withdrew its market authorization for this product, due to a lack of reimbursement, the biotech is focusing on another stem cell therapy, Cx601, in addition to AlloCSC-01. Under development for Crohns disease, Cx601 is currently awaitingEMA approval and is in phase III trials in the US.

For a late-stage clinical company, TiGenix has a low market cap of191M. Even so, the company seems to be doing well these days with the progress of Cx601 and AlloCSC-01.

If AlloCSC-01 obtains market approval, it could treat the more than 1.9 millionpeople affected by AMI, a major cause of heart failure. So far, most treatments are palliative or restore myocardial function by angioplasty and insertion of a stent to support the vascular lumen.

Stem cell therapy of the heart is definitely not a new topic, but many trials have been conducted using the patients own stem cells derived from the bone marrow. A recent meta-analysisof such trials has suggested that these therapies are safe, but do not enhance cardiac function. TiGenixs approach using allogeneic heart-derived stem cells may offer a new and promisingopportunity in thefield.

Images via shutterstock.com / Liya Graphics andVeronika Zakharova

See the article here:
New Cardiac Stem Cell Therapy passes Phase I/II Trials - Labiotech.eu (blog)

To Read More: New Cardiac Stem Cell Therapy passes Phase I/II Trials – Labiotech.eu (blog)
categoriaBone Marrow Stem Cells commentoComments Off on New Cardiac Stem Cell Therapy passes Phase I/II Trials – Labiotech.eu (blog) | dataMarch 14th, 2017
Read All

At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific … – Benzinga

By daniellenierenberg

On March 8-9 in Boston, stem cell medicine biotechnology start-up Asymmetrex led attendees at the 6th Annual Clinical Trials Supply New England 2017 conference in discussions about the need for quality controls for the supply of tissue stem cells used for treatments in either FDA-approved clinical trials or unregulated private stem cell clinics. Though these two stem cell treatment settings are often contrasted regarding their safety and effectiveness, Asymmetrex stressed that patient care and research progress is compromised in both because of the lack of essential quality control tests for the number and quality of transplanted tissue stem cells.

Boston, MA (PRWEB) March 14, 2017

At the 6th Annual Clinical Trials Supply New England 2017 conference, held in Boston from March 8-9, James Sherley, M.D., Ph.D., director of Asymmetrex, led discussions that evaluated the quality of U.S. supplies of stem cells used in clinical trials compared to private stem cell clinics. Private stem cell clinics have been criticized for not employing research standards that are necessary to establish the therapeutic effectiveness of treatments with statistical confidence. In part because of this difference in practice, they are also often accused of making unproven claims about the effectiveness of their therapies.

Sherley presented comparisons of key operational elements to argue that, given good intent in both settings, the two different settings of stem cell treatments had both distinct and shared shortcomings. He noted, however, that the most significant shortcoming, which stem cell clinical trials and private stem cell clinics share, was perennially overlooked.

Based on the number of reported stem cell clinical trials and private stem cell clinics, Sherley estimated that close to a quarter-million patients in the U.S. now receive stem cell treatments each year. Though many of these occur within FDA-approved clinical trials, their number is dwarfed nearly 10 times by the number of treatments that occur in private stem cell clinics. It shocked the audience of clinical trial suppliers to learn that there was no stem cell quality control test performed for any of these many treatments.

Even for approved stem cell medicine treatments like bone marrow transplantation and umbilical cord blood transplant, there is no stem cell-specific quality control test available. Counts of total cells are made, but these do not adequately predict stem cell number or function. Biomarkers designated for tissue stem cells are also expressed by stem cells' more abundant non-stem cell products. So, the biomarkers lack sufficient specificity to be used to count and monitor tissue stem cell function.

Without a quality control test for tissue stem cell number, stem cell treatments in all settings proceed without knowing the dose of treating tissue stem cells. This previously unavoidable therapeutic blind spot creates an instant treatment risk. It also precludes effective analyses to optimize treatment procedures, to compare different treatments, or to relate treatment outcomes to tissue stem cell dose. Without knowing stem cell dose, the interpretation of any stem cell treatment in terms of stem cells as the responsible agents is compromised.

In this context, Sherley announced briefly to attendees that Asymmetrex's new AlphaSTEM Test for counting adult tissue stem cells and providing data on their viability and tissue cell renewal function represented the needed first quality control test for tissue stem cell treatments, whether in clinical trials, in private stem cell clinics, or approved therapies. In particular, he indicated that both stem cell treatment patients and progress in stem cell medicine would benefit from existing clinical trial supply companies developing into future private stem cell clinic supply companies to insure the quality of stem cell treatment preparations. Sherley said that, of course, their partnership with Asymmetrex to implement its new stem cell-specific quality control test was an all around best solution for accelerating progress in stem cell transplantation medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex's founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company's patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex's focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/03/prweb14146903.htm

See more here:
At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific ... - Benzinga

To Read More: At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific … – Benzinga
categoriaBone Marrow Stem Cells commentoComments Off on At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific … – Benzinga | dataMarch 14th, 2017
Read All

‘Butterfly Boy’ steels himself for second stem-cell transplant | Ottawa … – Ottawa Sun

By daniellenierenberg


Ottawa Sun
'Butterfly Boy' steels himself for second stem-cell transplant | Ottawa ...
Ottawa Sun
Bracing for his second stem-cell transplant in seven months, Jonathan Pitre knows all too well the mountain in front of him, its hardships and precipices.

and more »

Go here to read the rest:
'Butterfly Boy' steels himself for second stem-cell transplant | Ottawa ... - Ottawa Sun

To Read More: ‘Butterfly Boy’ steels himself for second stem-cell transplant | Ottawa … – Ottawa Sun
categoriaBone Marrow Stem Cells commentoComments Off on ‘Butterfly Boy’ steels himself for second stem-cell transplant | Ottawa … – Ottawa Sun | dataMarch 14th, 2017
Read All

Would You Slather Blood and Breast Milk on Your Face? – Racked

By Dr. Matthew Watson

Vampire facials sound like a totally modern sci-fi development, but people have thought that drinking or slathering on blood can heal and renew for millennia. Pliny the Elder, nearly 2,000 years ago, wrote, [e]pileptic patients are in the habit of drinking the blood even of gladiators, draughts teeming with life. Elizabeth Bthory, a noblewoman from early modern Hungary, was said to have murdered virgins and then bathed in their blood in order to retain her youth. (Its worthwhile to note that King Louis XV and Marie Antoinette were also accused of bathing in their subjects blood.) In the stories, Bthory literally soaks up the youth of virgins via contact with their blood.

We think topically applied and ingested blood, bones, organs, and cells are magical sources of life force, health, and youth that somehow surpass the efficacy of less gory, more common ingredients.

The tales of blood baths seem spurious to say the least, and apparently theyre not backed up by primary evidence. But the fact that people have been passing the stories along for centuries tells us something about how we think. Even now, we seem to really dig the idea of applying or consuming human cells for the purpose of absorbing beauty and health from them. Vampire facelifts and Dr. Barbara Sturms MC1 cream make use of plasma from ones own blood drawn and separated in-office to supposedly renew skin. We think topically applied and ingested blood, bones, organs, and cells are magical sources of life force, health, and youth that somehow surpass the efficacy of less gory, more common ingredients.

Ingredients associated with conception, birth, and nursing seem to particularly excite us. Semen facials inadvisable and groan-worthy seem to make the rounds again when clicks are needed. In Korea, the brand Isa Knox uses recombinant human placenta protein (rHPP-8TM) in the Tervina line, supplied by the CHA Placenta Institute (part of the CHA Global Medical Network that includes a university medical school and institutes for stem cell and cosmetics research).

In the case of human stem cell skincare, companies have slapped a veneer of science on our old magical beliefs to ratchet up prices and expectations.

The idea of human ingredients is so seductive that people pay extra for them even when theyre not actually in the products. A Korean beauty product nicknamed mothers milk, Eureque Muru Mor Cream, contains no human milk, just baby powder fragrance and animal milk extracts that are supposed to be similar to human breast milk. If youre looking for the real deal, check out Mud Facial Bar, which offers an ethically sourced, $10 breast milk add-on for its facials.

In the case of human stem cell skincare, companies have slapped a veneer of science on our old magical beliefs to ratchet up prices and expectations. Stem cells here Im talking about pluripotent human stem cells can be manipulated to become any cell type in the human body under the right conditions and divide essentially without limit to replenish other cells as long as the person or animal is still alive according to the National Institutes of Health.

The twist is that stem cell skincare brands such as Lifeline Skin Care dont actually use whole, live human stem cells in their products. An actual stem cell would need to be kept alive in a skin cream, and that would certainly be challenging to accomplish, according to cosmetic chemist Kelly Dobos. Lifelines parent company, International Stem Cell Corporation, extracts human growth factors from stem cells by stimulating unfertilized eggs. Its the growth factors which stimulate cell growth, differentiation, healing, and proliferation that end up bottled, not the whole stem cells.

There really isn't any concrete, unbiased research to support the use of epidermal growth factors (EGF).

I asked Stephen Alain Ko, cosmetic chemist and blogger at kindofstephen, whether applying growth factors to skin makes sense. He wrote via email, [t]here really isn't any concrete, unbiased research to support the use of epidermal growth factors (EGF) on healthy human skin, and there is also a concern that EGF can also be involved in certain cancer growth as well. Ko noted that Oprah-recommended SkinMedicas TNS Essential Serum ($281 for one ounce) faces a California class action lawsuit claiming the company failed to disclose cancer risks associated with applying human growth factors to skin.

When asked about Skinmedicas TNS Essential Serum, Dobos wrote, [a]t $281 for one ounce and questionable science backing the ingredient claims, I would opt for a less expensive skin care product. Skincare companies dont need to make extravagant claims about the power of stem cell-derived ingredients, or even use whole human stem cells in their products; simply mentioning stem cell taps into long-held beliefs about the power of wearing and consuming human cells and our wallets.

Link:
Would You Slather Blood and Breast Milk on Your Face? - Racked

To Read More: Would You Slather Blood and Breast Milk on Your Face? – Racked
categoriaSkin Stem Cells commentoComments Off on Would You Slather Blood and Breast Milk on Your Face? – Racked | dataMarch 14th, 2017
Read All

Bone marrow recipient encouraging others to "Be the Match" – KXLY Spokane

By JoanneRUSSELL25

SPOKANE, Wash. - A simple cheek swab and a few minutes of your time could save the life of someone in need of a bone marrow transplant.

In 2015, 34-year-old Danielle Vaughan had a stem cell transplant to save her life. For nearly a decade she suffered from mysterious symptoms and illnesses.

"So I had these spin and brain lesions that were very scary," said Danielle Vaughan of Spokane. "I had seizures. I was seeing doctors at Stanford, University of Washington and in Spokane, trying to figure out what was going on."

Eventually, doctors diagnosed Vaughan with Common Variable Immune Deficiency. Her sister, Dina Medin, also had the disorder and underwent a bone marrow transplant a few years ago. The sisters are two of six people in the world with CVID who have had transplants.

"All other treatment options had failed. There was nothing else, that was the only option," said Vaughan.

In September of 2015, Vaughan traveled to Seattle to prepare for the transplant. Vaughan's medical team turned to Be The Match, a national bone marrow donor registry to find her a match. Vaughan said 44 people came back as a perfect match. Her donor was a 27 year old man from the United States. She'd love to meet him one day.

"I would like to say thank you for really giving me a second chance at life. But mostly giving me the opportunity to watch my kids grow," said Vaughan.

Vaughan is now encouraging others to join Be The Match.

"You don't know who you could be helping and you are going to save that person's life," said Vaughan.

The Dairy Queen in Post Falls at 3560 E Seltice Way is hosting a Be The Match donor sign up on Thursday, March 16th from 1:45 p.m.- 4:00 p.m. To register all you need to do is fill out paperwork and swab the inside of your cheek with a special Q-tip.

See the rest here:
Bone marrow recipient encouraging others to "Be the Match" - KXLY Spokane

To Read More: Bone marrow recipient encouraging others to "Be the Match" – KXLY Spokane
categoriaBone Marrow Stem Cells commentoComments Off on Bone marrow recipient encouraging others to "Be the Match" – KXLY Spokane | dataMarch 12th, 2017
Read All

This Holi, let your skin soak in benefits of Dead Sea Minerals – The Siasat Daily

By JoanneRUSSELL25

New Delhi [India]: Bura na mano holi hai., said Reena and ran away smearing a fistful of artificial colours on her sisters face.

Reena could have never imagined the after-effect this little prank would have on her sisters skin.

The festival of Holi can be a nightmare for people who are allergic to colours. While a couple of measures can be taken beforehand to prevent the skin from any damage, artificial colours can be nasty and can take time to leave your skin.

While a few like to protect themselves from the harsh colours and chemicals, fewer still, pay any heed to the potential skin damage before setting out to have fun.

Most of the inorganic colours have harmful chemicals that can cause allergies, reddening of the skin and burning sensation. Therefore, in order to usher in the festival of colours with pomp and celebration, it is essential to make sure that your skin comes out of the colour explosion perfectly fine.

Instead of scrubbing too much soap or heading to a beauty salon to get rid of the stubborn colours, this Holi, try your hand at Dead Sea Minerals that are high on magnesium, sodium and potassium, says Manisha Chopra, Co-Founder, SeaSoul Cosmeceuticals.

Dead Sea salts can act as an effective exfoliating agent and cleanser. To remove the stubborn colours, try out the dead sea facial mud mask that is loaded with essential ingredients such as Moroccan Argan oil, plant stem cells, noni fruit, goji berries, dead sea minerals, squalane, Aloe Vera, grape seed oil, sodium hyaluronate and Glycerin.

They dramatically help to clear the skin of all impurities and give a transformative effect on the face. Dead Sea Minerals help to get rid of the nasty colours and let you gain back smooth and healthy skin.

The products infused with Dead Sea salts are gentle and safe for all skin types as they are free of parabens and sulphates. Several medical journals have long exalted Dead Sea muds ability to promote radiance as well as its other therapeutic benefits for chronic skin conditions.

A facial polish works amazingly to get rid of the Holi colour as it removes the dead skin which has colours & then polishes the skin & cleanses the skin removing off the Holi colours. After removal of the colour, apply Dead Sea mud mask.

After removing the mask, apply Vitamin C serum to save your skin from after effects of Holi colours.

According to researchers, the Dead Sea water consists of 32% salts with a relatively high concentration of 21 minerals such as magnesium, calcium, bromide and potassium. The calcium present in the Dead Sea salt helps to cleanse pores and soothes and relieves the skin cells.

Magnesium works as an anti-allergic agent and boosts the metabolism of cells. The bromide present in the salt heals and relieves skin disorders and acts as an anti-inflammatory agent.

Sodium Chloride nourishes and hydrates skin cells and removes toxic waste, improving its permeability. Zinc promotes the natural regulation of cell growth and regeneration. It also aids in cell renewal and stimulates collagen and renews skin.

A great antioxidant, this mineral is a free-radical scavenger. It also improves anti-acne properties, anti-inflammatory properties and is a natural UV-rays blocker.

Thus, this Holi, steer clear of any rashes or breakouts on your skin as a result of stubborn colours and opt for miraculous Dead Sea products and play Holi stress-free.

Dead Sea salts can be found in facial care products such as cleansers, toners, moisturizers and masks. Avail the benefits of the wonderful minerals present in the Dead Sea and get ready to celebrate Holi to the fullest. (ANI)

Link:
This Holi, let your skin soak in benefits of Dead Sea Minerals - The Siasat Daily

To Read More: This Holi, let your skin soak in benefits of Dead Sea Minerals – The Siasat Daily
categoriaSkin Stem Cells commentoComments Off on This Holi, let your skin soak in benefits of Dead Sea Minerals – The Siasat Daily | dataMarch 12th, 2017
Read All

‘Butterfly Boy’ steels himself for second stem-cell transplant – Ottawa Citizen

By daniellenierenberg


Ottawa Citizen
'Butterfly Boy' steels himself for second stem-cell transplant
Ottawa Citizen
Bracing for his second stem-cell transplant in seven months, Jonathan Pitre knows all too well the mountain in front of him, its hardships and precipices. So he's doing ... Pitre will face the transplant alongside his mother, Tina Boileau, who will ...

and more »

Link:
'Butterfly Boy' steels himself for second stem-cell transplant - Ottawa Citizen

To Read More: ‘Butterfly Boy’ steels himself for second stem-cell transplant – Ottawa Citizen
categoriaSkin Stem Cells commentoComments Off on ‘Butterfly Boy’ steels himself for second stem-cell transplant – Ottawa Citizen | dataMarch 12th, 2017
Read All

Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the … – Yahoo Finance

By daniellenierenberg

MILPITAS, Calif.--(BUSINESS WIRE)--

Applied StemCell (ASC), a leading stem cell and genome-editing company with a goal to advance genome editing and stem cell technologies for biomedical research and clinical applications, welcomes Dr. Michele Calos as a member of the companys Scientific Advisory Board (SAB).

Dr. Michele Calos is a Professor of Genetics at the Stanford University School of Medicine, Vice President of the American Society of Gene and Cell Therapy, and has served as an Advisory Committee member for the US FDA, grant review panels for the NIH and NSF, and on numerous editorial review committees of scientific journals. She is a leader in the field of molecular genetics and has developed several novel vector systems for genetic manipulation of mammalian cells. In particular, she developed novel methods for sequence-specific integration in mammalian cells using the C31 phage integrase system. A similar integrase system was also successfully used in site-specific integration in human ES and iPS cells. For this work, Dr. Calos holds a joint patent application with Applied StemCells Chief Scientific Officer, Dr. Ruby Yanru Chen-Tsai and several other Stanford researchers. Dr. Calos pioneering work with C31 integrase also set the scientific stage for ASCs TARGATT integrase technology, which was co-developed by Dr. Chen-Tsai and Dr. Liqun Luo of Stanford University for gene modification in mouse models.

We are extremely pleased to have Dr. Calos join as a member of our scientific advisory board. With her impressive background in integrase gene modification technology and gene therapy, Dr. Calos will be an invaluable guide in furthering expansion of our genome editing platforms and our gene/cell therapy pipeline, said Ruby Yanru Chen-Tsai, Ph.D., Co-founder and Chief Scientific Officer of Applied StemCell.

Dr. Calos and her research team are currently focused on gene therapy and genome engineering for the treatment of Duchenne and Limb Girdle Muscular Dystrophies and developing further novel strategies for gene and cell therapy.

About Applied StemCell, Inc.

Applied StemCell, Inc. is a leading stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT and CRISPR/Cas9. For more information, please visit http://www.appliedstemcell.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005063/en/

View original post here:
Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the ... - Yahoo Finance

To Read More: Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the … – Yahoo Finance
categoriaIPS Cell Therapy commentoComments Off on Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the … – Yahoo Finance | dataMarch 12th, 2017
Read All

VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell – GlobeNewswire (press release)

By LizaAVILA

March 10, 2017 15:16 ET | Source: NASDAQ, Inc.

ADVISORY, March 10, 2017 (GLOBE NEWSWIRE) --

What:VistaGen Therapeutics Inc. (Nasdaq:VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Shawn K. Singh, CEO & Director, will ring the Closing Bell.

Where:Nasdaq MarketSite 4 Times Square 43rd & Broadway Broadcast Studio

When:Monday, March 13, 2017 3:45 p.m. to 4:00 p.m. ET

VistaGen Contact:Mark A. McPartland (650) 577-3600 IR@vistagen.com

Nasdaq MarketSite:Emily Pan (646) 441-5120 emily.pan@nasdaq.com

Feed Information:Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page: http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page: http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page: http://nasdaq.tumblr.com/

Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About VistaGenVistaGen Therapeutics, Inc.(NASDAQ:VTGN), is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders. VistaGen's lead CNS product candidate, AV-101, is a new generation oral antidepressant drug candidate in Phase 2 development. AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the U.S. National Institute of Mental Health (NIMH)in a Phase 2a monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 280-patient Phase 2b study of AV-101 as an adjunctive treatment for MDD patients with inadequate response to standard, FDA-approved antidepressant therapies. Dr. Maurizio Fava of Harvard University will be the Principal Investigator of the Phase 2b study. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including chronic neuropathic pain, epilepsy, Parkinson's disease and Huntington's disease, where modulation of the NMDAR, AMPA pathway and/or key active metabolites of AV-101 may achieve therapeutic benefit.

VistaStem Therapeutics is VistaGen's wholly owned subsidiary focused on applying human pluripotent stem cell(hPSC)technology, internally and with third-party collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities(NCEs),including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells. In December 2016, VistaGen exclusively sublicensed to BlueRock Therapeutics LP, a next generation regenerative medicine company established by Bayer AG and Versant Ventures, rights to certain proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease.

For more information, please visitwww.vistagen.comand connect with VistaGen onTwitter,LinkedInandFacebook.

About NasdaqNasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets.As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com.

-NDAQA-

Related Articles

Excerpt from:
VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell - GlobeNewswire (press release)

To Read More: VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell – GlobeNewswire (press release)
categoriaCardiac Stem Cells commentoComments Off on VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell – GlobeNewswire (press release) | dataMarch 11th, 2017
Read All

Stem cell swabbing for cancer-stricken Edmonton boy so successful it ran out of kits – Globalnews.ca

By JoanneRUSSELL25


Globalnews.ca
Stem cell swabbing for cancer-stricken Edmonton boy so successful it ran out of kits
Globalnews.ca
A Thursday evening stem cell swab event aimed at finding a match for an eight-year-old Edmonton boy with leukemia was so successful, it ran out of kits. Brady Mishio has acute myeloid leukemia, a cancer of the blood, and has undergone three rounds of ...

See the original post here:
Stem cell swabbing for cancer-stricken Edmonton boy so successful it ran out of kits - Globalnews.ca

To Read More: Stem cell swabbing for cancer-stricken Edmonton boy so successful it ran out of kits – Globalnews.ca
categoriaBone Marrow Stem Cells commentoComments Off on Stem cell swabbing for cancer-stricken Edmonton boy so successful it ran out of kits – Globalnews.ca | dataMarch 11th, 2017
Read All

Be The Match registry seeking blood and bone marrow donors – Fox17

By Dr. Matthew Watson


Fox17
Be The Match registry seeking blood and bone marrow donors
Fox17
A blood and marrow transplant replaces abnormal blood-forming stem cells with healthy cells. These are commonly used to treat blood cancers or other kinds of blood diseases that decrease the number of healthy blood cells in the body. Dr. Stephanie ...

More:
Be The Match registry seeking blood and bone marrow donors - Fox17

To Read More: Be The Match registry seeking blood and bone marrow donors – Fox17
categoriaBone Marrow Stem Cells commentoComments Off on Be The Match registry seeking blood and bone marrow donors – Fox17 | dataMarch 11th, 2017
Read All

Targeting cancer stem cells improves treatment effectiveness, prevents metastasis – Science Daily

By JoanneRUSSELL25


Science Daily
Targeting cancer stem cells improves treatment effectiveness, prevents metastasis
Science Daily
... Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma the most common head and neck cancer and the second-most common skin cancer, according to a new study.
Ascorbic Acid: New Potential In Targeting Cancer Stem CellsScience Times

all 16 news articles »

Read more from the original source:
Targeting cancer stem cells improves treatment effectiveness, prevents metastasis - Science Daily

To Read More: Targeting cancer stem cells improves treatment effectiveness, prevents metastasis – Science Daily
categoriaSkin Stem Cells commentoComments Off on Targeting cancer stem cells improves treatment effectiveness, prevents metastasis – Science Daily | dataMarch 11th, 2017
Read All

Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury – GlobeNewswire (press release)

By daniellenierenberg

March 09, 2017 07:03 ET | Source: Neuralstem, Inc.

-NSI-566 Achieved Robust Engraftment and Long-Term Survival After Transplantation-

- Data Published in Journal of Neurotrauma-

GERMANTOWN, Md., March 09, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced the recent publication of preclinical data on NSI-566 spinal cord-derived neural stem cells in Journal of Neurotrauma. These data showed robust engraftment and long-term survival of NSI-566 post transplantation in a rat model of penetrating ballistic-like brain injury (PBBI). NSI-566 is Neuralstems lead stem cell therapy candidate.

The study entitled, Amelioration of penetrating ballistic-like brain injury induced cognitive deficits after neuronal differentiation of transplanted human neural stem cells," was led by Ross Bullock, M.D., Ph.D., The Miami Project to Cure Paralysis, University of Miami School of Medicine. These are the first data from the 4-year proof-of-concept research program, funded by the United States Department of Defense, for NSI-566 in traumatic brain injury.

These data on NSI-566 are encouraging, particularly since researchers have long been challenged to achieve durable engraftment and survival of neural stem cells after transplantation, said Dr. Bullock. No long-term treatment beyond physical therapy is currently available to restore cognition after a traumatic brain injury. Transplantation of stem cells into the injured brain may allow a unique replacement therapy and fill a significant medical need.

Researchers transplanted NSI-566 into rats 7-10 days after PBBI. The rats were immunosuppressed to enable survival of NSI-566 neural stem cells. Robust engraftment with evidence of prominent neuronal differentiation was observed after 4 months, and axons from grafted cells extended a significant distance from the graft site along host white matter tracts.

These data continue to support our research and development platform. The results provide additional insight into our proprietary regionally specific stem cells and their potential benefits in nervous system disorders, said Karl Johe, Ph.D., Chief Scientific Officer, Neuralstem. We look forward to additional preclinical data from this collaboration with Dr. Bullocks group to support the potential use of NSI-566 in traumatic brain injury.

About Neuralstem Neuralstems patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are being developed as potential therapies for multiple central nervous system diseases and conditions.

Neuralstems technology enables the discovery of small molecule compounds by systematic screening chemical compounds against its proprietary human hippocampal stem cell line. The screening process has led to the discovery and patenting of molecules that Neuralstem believes may stimulate the brains capacity to generate new neurons, potentially reversing pathophysiologies associated with certain central nervous system (CNS) conditions.

The company has completed Phase 1a and 1b trials evaluating NSI-189, a novel neurogenic small molecule product candidate, for the treatment of major depressive disorder or MDD, and is currently conducting a Phase 2 efficacy study for MDD.

Neuralstems stem cell therapy product candidate, NSI-566, is a spinal cord-derived neural stem cell line. Neuralstem is currently evaluating NSI-566 in three indications: stroke, chronic spinal cord injury (cSCI), and Amyotrophic Lateral Sclerosis (ALS).

Neuralstem is conducting a Phase 1 safety study for the treatment of paralysis from chronic motor stroke at the BaYi Brain Hospital in Beijing, China. In addition, NSI-566 was evaluated in a Phase 1 safety study to treat paralysis due to chronic spinal cord injury as well as a Phase 1 and Phase 2a risk escalation, safety trials for ALS. Subjects from all three indications are currently in long-term observational follow-up periods to continue to monitor safety and possible therapeutic benefits.

Cautionary Statement Regarding Forward Looking Information This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as expect, anticipate, intend, plan, believe, seek or will. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstems periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2015, and Form 10-Q for the nine months ended September 30, 2016, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Related Articles

Germantown, Maryland, UNITED STATES

Neuralstem, Inc. Logo

LOGO URL | Copy the link below

Formats available:

Read the original post:
Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury - GlobeNewswire (press release)

To Read More: Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury – GlobeNewswire (press release)
categoriaSpinal Cord Stem Cells commentoComments Off on Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury – GlobeNewswire (press release) | dataMarch 10th, 2017
Read All

Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM… – RTT News

By NEVAGiles23

The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of March 9, 2017.

GAINERS

1. Ocera Therapeutics Inc. (OCRX)

Gained 71.82% to close Thursday's trading at $1.89.

News: The Company reported additional encouraging results from its Phase 2b STOP-HE study of intravenous (IV) OCR-002 in hospitalized patients with Hepatic Encephalopathy.

The initial STOP-HE results, reported in January 2017, had demonstrated highly statistically significant reduction in ammonia levels over placebo, strong evidence of benefit across multiple endpoints with higher doses (15g, 20g), clinical improvement dose trend, increased responder rate with increased dose and superiority over placebo at all doses. OCR-002 was also safe and well-tolerated.

The additional study data revealed on Thursday indicates that IV OCR-002 provided clinical benefit over placebo in other parameters as well, such as the Physician Overall Evaluation, Model for End-Stage Liver Disease (MELD) scores, and in renal function as measured by the change from baseline in Blood Urea Nitrogen (BUN) levels.

2. Cymabay Therapeutics Inc. (CBAY)

Gained 20.29% to close Thursday's trading at $4.09.

News: The Company will provide a corporate overview at the 29th Annual ROTH Conference on March 13th and at the Oppenheimer 27th Annual Healthcare Conference on March 21st.

Near-term catalysts:

- The results from phase II study of Cymabay's investigational drug Seladelpar in primary biliary cholangitis are expected in 3Q 2017. - The company's most advanced product candidate is Arhalofenate for treatment of gout, which has completed phase II studies. The drug candidate is licensed to Kowa Pharmaceuticals America, Inc. in the U.S.

Licensing discussions for other territories are underway. Ex-US licensing agreement for Arhalofenate is expected to be inked this year.

3. Neuralstem Inc. (CUR)

Gained 19.64% to close Thursday's trading at $5.30.

News: The preclinical data of the Company's NSI-566 spinal cord-derived neural stem cells in a rodent model of traumatic brain injury shows robust engraftment and long-term survival. The data are published in Journal of Neurotrauma.

NSI-566 is being explored in three indications: stroke, chronic spinal cord injury (cSCI), and Amyotrophic Lateral Sclerosis (ALS).

A phase I safety study of NSI-566 for the treatment of paralysis from chronic motor stroke is being conducted at the BaYi Brain Hospital in Beijing, China. In addition, NSI-566 was evaluated in a Phase 1 safety study to treat paralysis due to chronic spinal cord injury as well as a Phase 1 and Phase 2a risk escalation, safety trials for ALS. Subjects from all three indications are currently in long-term observational follow-up periods to continue to monitor safety and possible therapeutic benefits, according to the company.

Near-term catalyst:

-- Data from a phase II trial of NSI-189 for the treatment of major depressive disorder is expected in 3Q 2017.

4. Immunomedics Inc. (IMMU)

Gained 19.48% to close Thursday's trading at $6.01.

News: A global licensing agreement between Seattle Genetics (SGEN) and Immunomedics, worth over $2 billion, has been put on hold by a Delaware judge, following an injunction filed by venBio Select Advisor LLC, the largest shareholder of Immunomedics, to block the deal.

The license agreement between Seattle Genetics and Immunomedics was signed last month, and it involves antibody-drug conjugate, Sacituzumab govitecan, or IMMU-132.

Sacituzumab Govitecan (IMMU-132) is Immunomedics' lead investigational drug. As part of the agreement, Seattle Genetics is responsible for initiating phase III clinical trials of IMMU-132 in patients with metastatic triple-negative breast cancer (TNBC) and will be responsible for submitting the initial Biologics License Application to the FDA for accelerated approval.

VenBio is seeking to thwart the deal saying it undervalues the potential of IMMU-132. Now that a temporary restraining order has been placed on the deal, maybe there is an opportunity for a better deal.

5. Curis Inc. (CRIS)

Gained 20.78% to close Thursday's trading at $3.08.

News: The Company reported Q4 and full-year 2016 financial results and updated the progress of its pipeline.

The net loss for Q4, 2016 narrowed to $11.3 million or $0.08 per share on total revenue of $2.36 million. This compared with a net loss of $13.5 million or $0.10 per share and total revenue of $2.09 million in the year-ago period.

As for its clinical pipeline, the company noted that its phase I trial for CA-170 continues to progress on track through the dose escalation stage, and extension of the CA-170 Phase 1 study is all set to begin with enrollment of immunotherapy-nave patients in Korea and Spain, and with additional trial centers in other European countries projected to open in the second quarter.

A phase II trial of another drug candidate CUDC-907 in patients with relapsed/refractory MYC-altered diffuse large B cell lymphoma, or DLBCL , is expected to complete enrollment within the first half of this year.

6. VIVUS Inc. (VVUS)

Gained 16.35% to close Thursday's trading at $1.21.

News: The Company reported Q4 and full-year 2016 financial results.

VIVUS reversed to profit in the fourth quarter and full year of 2016 from net losses in the comparable year-ago periods.

Net income for the 2016 fourth quarter and full year was $56.6 million or $0.54 per share and $23.3 million or $0.22 per share, respectively, as compared to a net loss of $12.2 million or $0.12 per share and $93.1 million or $0.90 per share in 2015, respectively.

VIVUS had cash, cash equivalents and available-for-sale securities of $269.5 million at December 31, 2016.

The company noted that it will use its strong cash position for the acquisition and development of a new product pipeline to drive value creation for its stockholders while addressing the unmet needs of patients.

7. TG Therapeutics Inc. (TGTX)

Gained 16.26% to close Thursday's trading at $11.80. Shares of TG Therapeutics have been on the rise since announcing positive top line data from its phase III trial of TG-1101 in patients with high risk Chronic Lymphocytic Leukemia, dubbed GENUINE, on March 6, 2017.

News: The Company has priced an underwritten public offering of 5,128,206 shares of its common stock at a price of $9.75 per share.

Anticipated event: Q4 and full-year 2016 financial results and an update on business outlook for 2017 are slated to be presented on March 10, 2017.

LOSERS

1. InspireMD Inc. (NSPR)

Lost 37.56% to close Thursday's trading at $1.23.

News: The Company has priced its public offering of shares of Series C Convertible Preferred Stock, Series B warrants and Series C warrants.

Each share of Series C Convertible Preferred Stock is convertible into 4 shares of common stock at a conversion price equal to $1.60 per share. The Series B warrants have an exercise price of $2.00 per share of common stock and Series C warrants have an exercise price of $1.60 per share of common stock.

The gross proceeds from the offering are estimated to be up to $7.5 million. The offering is expected to close on or about March 14, 2017.

2. Cogentix Medical Inc. (CGNT)

Lost 13.12% to close Thursday's trading at $1.92.

News: The Company reported Q4 and full-year 2016 financial results.

Net loss for Q4 2016 widened to $18.57 million or $0.40 per share on revenue of $13.2 million. This compared with a net loss of $1.09 million or $0.04 per share and revenue of $13.64 million in the year-ago period.

3. BIOLASE Inc. (BIOL)

Lost 12.41% to close Thursday's trading at $1.20.

News: The Company reported Q4 and full-year 2016 financial results

The net loss for the fourth quarter of 2016 widened to $4.4 million or $0.07 per share as revenues declined to $13.8 million. This compared with a net loss of $2.5 million or $0.04 per share and revenue of $14.5 million in the fourth quarter of 2015.

4. Tandem Diabetes Care Inc. (TNDM)

Lost 11.63% to close Thursday's trading at $1.90.

News: The Company reported Q4 and full-year 2016 financial results.

The net loss for the fourth quarter of 2016 widened to $14.82 million or $0.48 per share as sales fell to $28.91 million. This compared with a net loss of $12.09 million or $0.40 per share and sales of $29.12 million in the fourth quarter of 2015. Tandem has also filed a registration statement on Form S-1 with the SEC relating to a proposed follow-on public offering of approximately $50 million of its common stock.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

See the original post:
Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM... - RTT News

To Read More: Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM… – RTT News
categoriaSpinal Cord Stem Cells commentoComments Off on Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM… – RTT News | dataMarch 10th, 2017
Read All

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community

By raymumme

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial
P&T Community
Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate, AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial Infarction (AMI). In addition, the second product candidate from the cardiac stem ...

and more »

See the original post here:
TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial - P&T Community

To Read More: TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community
categoriaCardiac Stem Cells commentoComments Off on TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial – P&T Community | dataMarch 10th, 2017
Read All

Cardiac research nets Holly Mewhort prestigious heart association award – UCalgary News

By NEVAGiles23

Numerous people may say they want to grow up to be a heart surgeon, but very few actually achieve that goal. Holly Mewhort, MD, PhD, is one who has done so. And thats not the only thing Mewhort, who is part of the Libin Cardiovascular Institute of Albertas cardiac surgical residency program, has accomplished.

She has also excelled in basic and translational research. She recently received international recognition for her work in cardiac research, winning the Vivien Thomas Young Investigator Award from the American Heart Association, a prestige award given to early investigators who are focusing on fundamental and applied surgical research.

That research was done as part of her PhD program, which she completed in June 2016 under the supervision of Libin Institutes Paul Fedak, MD, PhD. Fedak is a cardiac surgeon and basic/translational researcher who directs the Marlene and Don Campbell Family Cardiac Research Laboratory at the Cumming School of Medicine.

Research shows biomaterial can trigger healing in damaged heart muscle

Mewhorts research investigates the use of biomaterial in regenerating and restoring heart tissue in patients who had previously suffered a heart attack. The material, CorMatrix-ECM, is a connective tissue matrix surgically applied to damaged heart tissue to trigger healing.Mewhort describes the material as providing the scaffolding that holds cells together and influences their behaviour and survival.

Her research in this area began four years ago in the lab and has had great success. In preclinical trials, the project has shown that this bio-material can restore function to damaged heart muscle by promoting the formation of new blood vessel networks a process called vasculogenesis.

The investigators have completed a pilot clinical trial, which saw the patch applied to the heart tissue of a handful of patients during coronary bypass surgery. The results havent been published yet, but the data looks promising.

Mewhort is thrilled to be part of a research project that has been successfully translated from bench to bedside. If it works at the clinical trial level, this could be a game-changer for patients who have suffered a heart attack, she says, noting until now, there hasnt been a way of restoring function to damaged heart tissue in those patients.

Cardiac surgery research program is 'cutting edge'

Its also exciting for Mewhort to win the same award her mentor, Dr. Paul Fedak, received 14 years ago. He was also a cardiac surgery trainee pursuing a PhD, investigating stem cell regeneration of heart tissue. The fact that two researchers connected with the University of Calgary earned the same international award is impressive, as competition is stiff. Past winners have studied at such institutions as the University of Toronto, Duke and Stanford.

Fedak, who studied at the University of Toronto, was recruited to come to Calgary about a decade ago and has since set up a cutting-edge cardiac surgery research program. Mewhort is the first PhD graduate of his laboratory. As her mentor, Fedak, who, besides being an academic researcher is a full-time clinical heart surgeon, is pleased to see the program turning out well-respected young academic surgical scientists.

He says Mewhorts award fulfils another career goal, explaining that when he won the Vivien Thomas Young Investigator Award his desire became to see one of his students do the same. For Fedak, the award signifies the coming-of-age of academic cardiac surgeon training in Calgary.

This shows us how far we have come with our program, he says.

Receiving her mentors praise is a big deal for Mewhort, as Fedak was one of the reasons she chose to pursue her surgery training and PhD in Calgary. Mewhorts future looks bright as she continues her residency in cardiac surgery on campus with the ultimate goal of having an active surgical and research career, much like her mentor.

Here is the original post:
Cardiac research nets Holly Mewhort prestigious heart association award - UCalgary News

To Read More: Cardiac research nets Holly Mewhort prestigious heart association award – UCalgary News
categoriaCardiac Stem Cells commentoComments Off on Cardiac research nets Holly Mewhort prestigious heart association award – UCalgary News | dataMarch 10th, 2017
Read All

Amid advances in gene therapy, ‘bubble baby’ in SF gains hope – San Francisco Chronicle

By JoanneRUSSELL25

JaCeon Golden has only ever known the inside of hospitals. But the treatment hes receiving may have implications far beyond his as-yet isolated life.

Round-faced and big-eyed, with a perpetual pout that belies his sunny nature, he looks as healthy as any other 5-month-old. But JaCeon was born without a functioning immune system. Even the most banal of infections a cold, a diaper rash could be deadly.

Earlier this year, JaCeon became the first baby at UCSF Benioff Childrens Hospital at Mission Bay to undergo an experimental gene therapy treatment that, doctors hope, will nudge his body to build a new, robust immune system.

From right: Dannie Hawkins checks on her nephew Ja'Ceon Golden, who is being held by patient care assistant Grace Deng at UCSF Benioff Children's Hospital on Wednesday, March 8, 2017, in San Francisco, Calif. Golden, who is five months old, is diagnosed with severe combined immunodeficiency disease (SCID). He is a patient at UCSF, where he stays in a sterile room. The hospital is working on a new gene therapy treatment for SCID. Hawkins brought her nephew Golden from New Mexico for the experimental treatment.

From right: Dannie Hawkins checks on her nephew Ja'Ceon Golden, who...

So far, his results are promising. In a few weeks, JaCeons great aunt, whos also his guardian, hopes to introduce him to the world outside.

Am I going to see him smile when we walk out of here? Dannie Hawkins, 52, said with a glance at the baby, being fed from a bottle by a nurse wearing a gown and gloves. Hows he going to do in the free world?

It will be a while months, probably years before JaCeon is able to fully integrate with that wide world: go to school and birthday parties, ride a public bus, swim in a community pool. But that those activities may be in his future at all is extraordinary.

The treatment given to JaCeon is the result of decades of research into gene therapy that included a string of striking failures that led many doctors to abandon the pursuit altogether.

Gene therapy long had been considered a potential treatment for severe combined immunodeficiency disorder, or SCID, the condition JaCeon was born with, and some other genetic syndromes. The idea is to replace a single gene thats causing trouble.

Even as many doctors gave up on the promise of gene therapy, teams of stubborn scientists kept plugging away. And a few years ago, their experiments started to work, propelled by advances in the understanding of stem cells in this case, a type called hematopoietic stem cells that live in bone marrow and are responsible for generating blood and immune cells and improved methods of delivering genetic repairs.

JaCeon Golden is treated by patient care assistant Grace Deng (center) and pediatric oncology nurse Kat Wienskowski.

JaCeon Golden is treated by patient care assistant Grace Deng...

Now human gene therapy is being tested in trials at UCLA, where a team has treated 20 children with one type of SCID, and at UCSF in collaboration with St. Jude Childrens Research Hospital in Memphis. Both trials are funded by grants from the California Institute for Regenerative Medicine, the states stem cell agency, located in Oakland.

Researchers are studying similar therapies in hopes of curing genetic syndromes like sickle cell disease. And the stem cell agency is funding gene therapy research into potential treatments for HIV, brain cancer and Huntingtons disease, among others.

Gene therapy has been shown to work, the efficacy has been shown. And its safe, said Sohel Talib, a senior science officer at the state stem cell agency. The confidence has come. Now we have to follow it up.

JaCeon was born at a hospital in Las Cruces, N.M., and diagnosed with SCID just after birth as part of a standard newborn screening. He was flown to UCSF, one of a handful of facilities with expertise in SCID, when he was 3 weeks old. His great-aunt joined him about a month later, in November.

The immune disorder is commonly known as bubble baby disease, because until fairly recently kids born with it had to live in isolation, often in plastic bubbles in hospital rooms or their own homes to protect them from infections.

Babies born with SCID have a genetic mutation that leaves their immune system unable to develop disease-fighting cells. Without treatment, most will die within a year. Since the 1970s, some babies with SCID were cured with a bone-marrow transplant. But to be effective, a perfect match was required, almost always from a sibling, and only about a fifth of kids have such a match.

Ja'Ceon Golden is held by patient care assistant Grace Deng, as Deng bottle feeds Golden at UCSF Benioff Children's Hospital on Wednesday, March 8, 2017, in San Francisco, Calif. Golden, who is five months old, is diagnosed with severe combined immunodeficiency disease (SCID). He is a patient at UCSF, where he stays in a sterile room. The hospital is working on a new gene therapy treatment for SCID. Golden was brought from New Mexico for the experimental treatment.

Ja'Ceon Golden is held by patient care assistant Grace Deng, as...

The rest could undergo a bone marrow transplant from a partial match in JaCeons case, his great-aunt was one but even when that treatment was successful, kids were left with fragile immune systems that required constant maintenance with antibiotics and other boosts.

Gene therapy, though, may prove as effective as a bone marrow transplant from a perfect match.

The procedure starts with doctors harvesting stem cells from a babys own bone marrow, usually taken from the hip. In JaCeons case, his stem cells were sent in January to St. Jude in Memphis, where scientists are perfecting the gene-therapy delivery mechanism.

Sending away JaCeons stem cells was probably the most stressful time of my life, short of my own kids maybe being born, said Dr. Morton Cowan, the lead investigator of the UCSF trial, who has worked in SCID research for more than 30 years.

JaCeons stem cells were flown east over the first big weekend of major storms in California. Flights were being canceled around the clock, and doctors only had a window of about 36 hours to get the fresh cells to the labs in Memphis.

The trip was successful, but not without a hitch. After the cells were engineered and were being sent back to California, the material for a few heart-stopping hours got lost in the mail.

In a couple of months, Cowan said, he hopes to be able to do the gene-therapy delivery at UCSF labs, avoiding the travel headaches.

For now, that still happens at St. Jude. Doctors used a virus in fact, HIV, the virus that causes AIDS to deliver the gene therapy to JaCeons stem cells. The virus is neutered, with all of the disease-causing pieces inside removed.

Whats left is a missile-like shell designed to infiltrate a cell and deliver whatever payload doctors have inserted inside in this case, a healthy gene that will restore the stem cells ability to build normal immune cells.

Back in San Francisco, the cells were infused into JaCeon via a port in his chest. Because theyre his own cells, there was no fear his body would reject them.

He did have to undergo mild chemotherapy to kill off some of his own bone marrow and make room for the re-engineered stem cells to roost, but UCSF has been developing a technique for limiting the dosage of chemotherapy given in gene therapy procedures.

JaCeon suffered no obvious side effects from either the stem cell infusion or the chemotherapy drugs, doctors said.

Hes just thriving. Hes just hes great, Cowan said. He added, We cant open the Champagne just yet, but early tests show the new gene is active, and JaCeon has had an uptick of certain immune cells.

The infusion procedure took just 20 minutes, and JaCeon slept through it, but it felt momentous nonetheless.

It had been difficult to decide to enroll JaCeon in the trial, Hawkins said. Since she was a partial match for a bone marrow transplant, she had the option of giving him the traditional and well-tested therapy.

Shed said to his doctors, So youre telling me hes a guinea pig? They told her, she recalls, If it works, he can open the door for other kids.

That night, as Hawkins slept on the decision, I kept waking up, waking up, all night long, she said. If there was a possibility he could save someone else ... she added, and then broke off in tears.

She spends about six hours with JaCeon every day, beginning each morning with a bath in sterile water, brought by nurses in special tubs. Shes constantly wiping down his toys, clothes, bedding and stuffed animals.

Ive changed a lot of diapers in my time, but this is way more complicated than with other kids, Hawkins said, demonstrating the multistep process she uses to prevent diaper rash.

Im not going to say its been easy, she said. But hes doing fine. I wouldnt have it any other way.

Erin Allday is a San Francisco Chronicle staff writer. Email: eallday@sfchronicle.com

Twitter: @erinallday

Go here to see the original:
Amid advances in gene therapy, 'bubble baby' in SF gains hope - San Francisco Chronicle

To Read More: Amid advances in gene therapy, ‘bubble baby’ in SF gains hope – San Francisco Chronicle
categoriaBone Marrow Stem Cells commentoComments Off on Amid advances in gene therapy, ‘bubble baby’ in SF gains hope – San Francisco Chronicle | dataMarch 10th, 2017
Read All

How ‘Cannibalism’ By Breast Cancer Cells Promotes Dormancy: A Possible Clue Into Cancer Recurrence – IFLScience

By NEVAGiles23

By studying the cannabilistic tendency of cancer cells, my research team has made some progress in finding out why.

The chances of recurrence and disease outcome vary with cancer subtype. About one-third of patients diagnosed with triple negative breast cancer, the most aggressive subtype, may experience a recurrence in another part of the body. This is called distant recurrence.

It has been difficult, if not impossible, to predict if and when the same cancer will recur and to stop it. Recurrent disease may arise from just a single cancer cell that survived the initial treatment and became dormant. The dormancy allowed it to hide somewhere in the body, not growing or causing harm for an unpredictable amount of time.

Determining what puts these dormant cells to sleep and what provokes them to wake up and begin multiplying uncontrollably could lead to important new treatments to prevent a demoralizing secondary cancer diagnosis.

Recently, my research team and I uncovered several clues that might explain what triggers these breast cancer cells to go dormant and then reawaken. We showed that cell cannibalism is linked to dormancy.

How do bone stem cells affect breast cancer?

Breast cancer can recur in the breast or in other organs, such as the lungs and bone. Where breast cancer decides to grow depends largely on the microenvironment. This refers to the cells that surround it, including immune cells, cells comprising blood vessels, fibroblasts and the select proteins they produce, among other factors.

Over a century ago, a surgeon named Stephen Paget famously compared the organ-specific prevalence of cancer metastasis to seeds and soil. Because breast cancer often relapses in bones, in this metaphor, which still holds forth today, the bone marrow provides a favorable microenvironment (the soil) for dormant breast cancer cells (the seeds) to thrive.

Just as seeds need soil to provide an environment for growth, cancer cells need an environment to grow. From http://www.shutterstock.com

Thus, a substantial amount of recent work has involved trying to determine the role in cancer dormancy of a special type of cell, called mesenchymal stem cells (MSCs). These are found in bone marrow.

MSCs in bone marrow are highly versatile. They are able to form bone, cartilage and fibrous tissue, as well as cells that support the immune system and formation of blood. They are also known to travel to sites of tissue injury and inflammation, where they aid in healing.

Breast cancer cells readily interact with MSCs if they meet in the bone marrow. They also readily interact if the breast cancer cells recruit them to the site of the primary tumor.

My research team and I recently focused on potential outcomes of these cellular interactions. We found an odd thing happens, which may provide insight into how these breast cancer cells hide for a long time.

In the laboratory setting, we produced breast tumor models containing MSCs. We also re-created the hostile conditions that naturally challenge developing tumors in patients, such as localized nutrient deficits caused by rapid growth of cancer cells and overcrowding.

See more here:
How 'Cannibalism' By Breast Cancer Cells Promotes Dormancy: A Possible Clue Into Cancer Recurrence - IFLScience

To Read More: How ‘Cannibalism’ By Breast Cancer Cells Promotes Dormancy: A Possible Clue Into Cancer Recurrence – IFLScience
categoriaBone Marrow Stem Cells commentoComments Off on How ‘Cannibalism’ By Breast Cancer Cells Promotes Dormancy: A Possible Clue Into Cancer Recurrence – IFLScience | dataMarch 10th, 2017
Read All

Kansas Stem Cell Center Close To First Clinical Trial – KMUW

By Dr. Matthew Watson

An adult stem cell center established by the Kansas Legislature in 2013 is almost ready for its first clinical trial.

Buddhadeb Dawn, executive director of the Midwest Stem Cell Therapy Center, told legislators Tuesday that the trial will focus on treating graft-versus-host disease and will begin after final approvals from the U.S. Food and Drug Administration.

Our goal was to do this (trial) in January, but we got delayed because of different things, Dawn said during a hearing of the House Health and Human Services Committee. So we are now hoping to start it perhaps in summer.

Based at the University of Kansas Medical Center in Kansas City, the stem cell center has analyzed trials done elsewhere and hosted a clinical trial sponsored by a biotech company that uses modified stem cells from bone marrow to treat stroke.

But the graft-versus-host disease trial would be the first homegrown one.

Graft-versus-host disease is a potential complication when a patient receives a transplant of tissue, like an organ or bone marrow, from another person.

The disease occurs when transplanted tissue fights the patients natural immune system, potentially damaging the liver, skin or other areas. Its a rare illness, with about 20,000 cases in the United States each year.

Rep. Randy Powell, a Republican from Olathe, said the trial was a welcome and exciting development. He said his wife is at risk for the illness following treatment for leukemia.

I know that graft-versus-host is a big thing, Powell said. I think my wife still has an annual checkup where they keep their eye out (to make sure) thats not sticking its head up and causing issues.

Dawn said the center would like to take the next step and move into clinical trials using adult stem cells to treat things like joint ailments, diabetes and amyotrophic lateral sclerosis, also known as Lou Gehrigs disease.

But the regulatory process takes time.

Wed like to be able to offer a portfolio of different disease conditions that adult stem cells can benefit, Dawn said. Im hoping that within the next five years we would at least have some FDA approval for treatment with adult stem cells for other conditions.

Dawn said successful trials could lead to more private investment dollars so we are self-sustaining at some point in the future.

The centers reliance on state funds has been a point of contention for fiscally conservative legislators in the past. Most of the facilitys budget still comes from the states payment, which was reduced by about $28,000 to $754,500 last year.

Thats far less than what stem cell research facilities in other states receive.

Doug Girod, executive vice president of the KU medical center, said that given the budget, Dawn and his small team have done remarkable work.

We could be 10 times bigger than we are and doing 10 times as much if we had the resources, Girod said. But I think were maximizing every opportunity we can with what we have right now.

The center was spearheaded by socially conservative legislators, including Sen. Mary Pilcher-Cook, to showcase adult stem cell research as an alternative to using stem cells derived from human embryos.

About $56,000 of its annual budget goes to educating the public about the differences between embryonic stem cells and adult cells and hosting an annual conference about advances in adult stem cell treatment.

Rep. John Wilson, a Democrat from Lawrence, said he initially was skeptical about the facility because he thought the Legislature was inserting itself into a religious or philosophical fight. But he said his attitude has changed.

Im glad that despite my opposition to it the state has gone forward with funding some really terrific research, Wilson said. My concern now is how do we take it to the next level so all of this hasnt been for nothing.

Andy Marso is a reporter for KMUW's Kansas News Service, a collaboration of KMUW, Kansas Public Radio and KCUR covering health, education and politics in Kansas. You can reach him on Twitter@andymarso.

Read the original:
Kansas Stem Cell Center Close To First Clinical Trial - KMUW

To Read More: Kansas Stem Cell Center Close To First Clinical Trial – KMUW
categoriaBone Marrow Stem Cells commentoComments Off on Kansas Stem Cell Center Close To First Clinical Trial – KMUW | dataMarch 10th, 2017
Read All

Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient – Detroit Free Press

By NEVAGiles23

Subscribe today for full access on your desktop, tablet, and mobile device.

472

Let friends in your social network know what you are reading about

Get to know the Lions' newest linebacker, who agreed to a one-year deal to come to Detroit from Atlanta

Try Another

Audio CAPTCHA

Image CAPTCHA

Help

CancelSend

A link has been sent to your friend's email address.

A link has been posted to your Facebook feed.

Atlanta Falcons linebacker Paul Worrilow kisses his 15-month-old daughter, Julie, after the first day of training camp in Flowery Branch, Ga., on July 28, 2016.(Photo: Curtis Compton, Associated Press)

Height, weight: 6 feet, 230 pounds.

Joined the Lions:Worrilow, who turns 27 in May, agreed to a one-year contract with the Lions on Wednesday.

NFL career: He made the Atlanta Falcons in 2013 as an undrafted free agent after being a walk-on at Delaware. Worrilow was the Falcons' starting middle linebacker job in 2013-15. He led the team in tackles each of his first two seasons. Last season, the Falcons wanted to get faster at linebacker, so they drafted two, and Worrilow lost his job to rookie Deion Jones. Worrilow was relegated mostly tospecial teams in 2016 and played just four defensive snaps in the playoffs -- none in the Super Bowl.I know I can go and play good ball, Worrilow told the Atlanta Journal-Constitution. Whether if thats here or somewhere else.

Off the field:In 2011, he signed up for Delawares bone-marrow program. He underwent a six-hour procedure to donate peripheral blood stem cells to an anonymous 21-year-old leukemia patient.

Lions to make Ricky Wagner highest-paid RT; he's 'living his dream'

Contact Carlos Monarrez: cmonarrez@freepress.com. Follow him on Twitter @cmonarrez.

Download our free Lions Xtra app on your Apple and Android devices.

1:40

1:04

0:57

1:07

0:59

1:40

2:39

1:18

2:10

1:38

0) { %>

0) { %>

Read more:
Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient - Detroit Free Press

To Read More: Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient – Detroit Free Press
categoriaBone Marrow Stem Cells commentoComments Off on Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient – Detroit Free Press | dataMarch 10th, 2017
Read All

Page 402«..1020..401402403404..410420..»


Copyright :: 2024